ABERNETHY MATT (Chief Financial Officer) sold 5.1% of their position (2.31K shares) of NEUROCRINE BIOSCIENCES INC on the open market
Open‑market sale worth $363.3K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 1 sale
Filed: 9/15/2026ACC: 0001724097-26-000010
Officer· Chief Financial Officer
Since Mar 2026
0.00
Net shares
Net seller
$786.5K
Total sold
1
Open market trades
0B · 1S
3
Total transactions
5.02K acquired · 5.02K disposed
Non-Derivative Transactions3
Common Stock
Direct
Shares
+5.02K
Price / share
—
Trade value
—
% of position
11.7%
9/11/2026
42.81K→47.83K
Common Stock
Direct
Shares
−2.71K
Price / share
$156.22
Trade value
$423.20K
% of position
5.7%
9/11/2026
47.83K→45.12K
Common Stock
Direct
Shares
−2.31K
Price / share
$157.20
Trade value
$363.28K
% of position
5.1%
9/14/2026
45.12K→42.81K
Total
Net shares
+0.00
Net value
-$786.48K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/11/2026 | A · Award | +5.02K | — | — | 11.7% | 42.81K | 47.83K |
| Common Stock Direct | 9/11/2026 | F · Tax Withholding | −2.71K | $156.22 | $423.20K | 5.7% | 47.83K | 45.12K |
| Common Stock Direct | 9/14/2026 | S · Sale | −2.31K | $157.20 | $363.28K | 5.1% | 45.12K | 42.81K |
| Total | +0.00 | -$786.48K | ||||||
Derivative Transactions0
No derivative transactions reported